

## Heart Failure

Date written: August 2011

Final submission:

Author: Matthew Roberts

### GUIDELINES

#### CKD and kidney transplant recipients

- a. We recommend that an angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist be prescribed for patients with CKD (or kidney transplant) and heart failure (1B). The evidence of benefit in the general population is strong and there is reasonable data to suggest that these effects are similar in CKD.
- b. We recommend that a beta-blocker be prescribed for patients with CKD (or kidney transplant) and heart failure (1B). The evidence of benefit in the general population is strong and there is strong data to suggest that these effects are similar in CKD.
- c. There is insufficient evidence that the benefits of aldosterone antagonists in patients with CKD and heart failure outweigh the harms. Therefore we do not suggest that this therapy should be prescribed for all patients (ungraded).
- d. The anaemia of people with CKD and heart failure should be treated according to the CARI Guideline “Biochemical and Haematological Targets: Haemoglobin”. There is no evidence this should be modified for patients with heart failure (ungraded).
- e. The role of diuretic therapy in heart failure is to control the disturbance in extracellular fluid volume and there is no evidence of benefit in terms of cardiovascular outcomes (ungraded).
- f. In the absence of any evidence, patients with CKD or kidney transplant recipients who meet the criteria for an implantable device should be considered for such devices (ungraded).

#### Dialysis

- a. We suggest that patients receiving dialysis who have heart failure be prescribed an angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist (ungraded). This is based on there being strong evidence in the general population as there are no trials comparing these agents to placebo in patients undergoing dialysis.
- b. In the absence of *high-quality* evidence, we suggest that patients receiving dialysis who have heart failure be prescribed a beta-blocking agent (2C). This is based on there being strong evidence in the general population, strong data to suggest similar effects in CKD, and one randomised controlled trial in patients undergoing dialysis consistent with these data.
- c. The anaemia of people requiring dialysis who have heart failure should be treated according to the CARI Guideline “Biochemical and Haematological Targets: Haemoglobin”. There is no evidence this should be modified for patients with heart failure (ungraded).

## **Background**

Chronic kidney disease (CKD) and chronic heart failure (CHF) frequently co-exist. The mechanisms for this [1], and a potential classification of this “cardiorenal syndrome” [2], have been reviewed in depth by others. Risk factors such as hypertension and diabetes are common to both CKD and CHF. Many current treatment recommendations for the management of heart failure are based on the highest levels of evidence. However, most guidelines make no recommendations specific to patients with CKD. This guideline seeks to fill this gap.

The prevalence of heart failure or reduced systolic function is increased in patients with CKD compared to people with normal kidney function. In the Chronic Renal Insufficiency Cohort, a history of heart failure was reported by 15% of participants with a GFR<30mL/minute, compared to 5% in participants with GFR>60mL/minute [3]. Likewise, the prevalence of CKD, defined as a glomerular filtration rate (GFR) less than 60mL/minute, is very high in heart failure patients. In many trial cohorts, this prevalence is over one third and patients with heart failure who also have CKD have a greater mortality risk than patients with heart failure and normal kidney function [4]. In a randomised controlled trial population with severe heart failure, 50% of participants had a creatinine clearance less than 60mL/minute and reduced creatinine clearance was a stronger predictor of outcome than reduced left ventricular ejection fraction (LVEF) [5].

Heart failure is also a significant co-morbidity in end-stage kidney disease (ESKD). The prevalence of heart failure has been reported in between 31-40% of patients commencing dialysis [6, 7], and patients receiving dialysis who have co-morbid CHF have a greater mortality than those who don't have CHF [7, 8]. Patients receiving dialysis who have heart failure who receive a kidney transplant are at increased risk of adverse outcomes in the post-transplant period. Of 653 patients who had cardiac nuclear imaging before kidney transplant, 18% had a LVEF≤45% and these patients had between 2 to 5 times greater death, cardiac death and cardiac complications than patients with LVEF above this level [9].

Heart failure may also develop “de novo” after receiving a kidney transplant. Using United States Medicare Claims data, the incidence of de novo heart failure was estimated to be 10.2% at 12 months and 18.3% at 36 months [10]. For patients remaining on dialysis on the transplant waiting list, these incidences were 12.0% and 32.3%, respectively. In a retrospective study that used a clinical definition of heart failure, the cumulative incidence of de novo heart failure in patients who survived the first post-transplant year without heart failure was 3.6% at 5 years and 12.1% at 10 years [11].

However, the presence of heart failure or concerns about the development of heart failure should not preclude patients with ESKD from being considered for transplantation, because restoring kidney function with transplantation actually may improve cardiac function in such patients. In patients with heart failure and LVEF≤40% who received a kidney transplant at a single centre, LVEF improved from 31.6±6.7% before to 52.2±12.0% after receiving a kidney transplant (p=0.002) [12]. In a pivotal observational study of change in cardiac structure and function in 433 patients with ESKD from the 1980s, all 12 patients with systolic dysfunction before transplant had normal systolic function on echocardiograms following their transplant

[13]. Other studies have demonstrated improvements in left ventricular volumes and function following transplantation [14-16], including as early as 3 months following the procedure [17].

A unique contributing factor to heart failure in patients with ESKD is the cardiac effects of shunting blood from the arterial to the venous system through the arteriovenous fistulae for vascular access. Because successful kidney transplantation makes ligation of the arteriovenous fistula possible, this may be a therapeutic option in kidney transplant recipients. Ligation of the arteriovenous fistula in 20 kidney transplant recipients without heart failure resulted in a reduced left ventricular end-diastolic diameter and left ventricular mass index [18]. Cases of arteriovenous fistula-related high-output cardiac failure that has improved with ligation of the fistula have been reported [19]; however, the benefits of ligation of arteriovenous fistulae in kidney transplant recipients with heart failure have not been studied in any systematic way.

The objectives of this guideline are to summarise the available evidence from randomised controlled trials for treatment of heart failure *in patients with chronic kidney disease*. Data will be presented separately for patients in the following categories:

1. Patients with CKD defined by a GFR < 60 mL/minute not requiring dialysis, and kidney transplant recipients
2. Patients receiving dialysis

The following treatments will be considered:

1. Blockade of the renin-angiotensin system
2. Blockade of beta-adrenergic receptors
3. Aldosterone antagonists
4. Digoxin
5. Treatment of anaemia with erythropoiesis stimulating agents
6. Strategies to control volume state including diuretics
7. Use of Implantable Devices

The recommendations for patients with CKD and kidney transplant are grouped together because these patients are similar in terms of current actual kidney function, and there are no trials that specifically enrolled kidney transplant recipients with heart failure to study a heart failure intervention. It is accepted that they will be different in many ways such as time already spent undergoing dialysis and immunosuppression.

A number of randomised controlled trials have been performed in patients with heart failure that provide a strong evidence base underpinning many guideline recommendations [20-22]. Evidence for each therapy in patients without kidney disease is presented in the first section on “**Patients with CKD and kidney transplant recipients**”, along with a summary of the Australian National Heart Foundation Heart Failure Guideline [21, 22] for the respective therapies. This is not re-stated in the “**Dialysis**” section.

## **Search strategy**

**Databases searched:** MeSH terms and text words for kidney disease, and renal replacement therapy were combined with MeSH terms for cardiovascular disease

and all of the drugs used to treat cardiovascular disease – beta-adrenergic antagonists, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, digoxin, nitrates, calcium antagonists and alpha-antagonists. The Cochrane search strategy for randomised controlled trials was also applied. These were then combined with the following search terms to define cardiac failure: Heart Failure, Left Ventricular Dysfunction, and Dilated Cardiomyopathy; systolic dysfunction, congestive cardiac failure and congestive heart failure were searched as “text words”. Ovid MEDLINE (1950-March 2008) was the database searched.

**Date of searches:** 19 March 2008

## **What is the evidence?**

### **Patients with CKD (GFR<60mL/minute) and kidney transplant recipients**

#### **1. Blockade of the renin-angiotensin system**

##### *Evidence from studies of patients without CKD*

In patients with heart failure, including those patients with heart failure after acute myocardial infarction, treatment with an angiotensin-converting enzyme inhibitor reduced the risk of death by 20% (odds ratio 0.80, 95% confidence interval 0.74-0.87,  $p<0.001$ ) [23]. Reinfarction, admission for heart failure or a composite of these events with mortality were also reduced. Angiotensin receptor blockers also reduce mortality when compared to placebo, but not when compared directly to angiotensin-converting enzyme inhibitors [24], and may reduce hospital admissions for heart failure when added to angiotensin-converting enzyme inhibitors compared to angiotensin-converting enzyme inhibitors alone [24, 25].

##### *National Heart Foundation guideline for the general population:*

- ACE inhibitors are recommended in systolic heart failure (LVEF<40%) at all levels of symptoms (Grade A) and at maximum tolerated dose (Grade B)
- Angiotensin receptor antagonists are recommended as an alternative where ACE inhibitors are not tolerated, or in addition to ACE inhibitors where patients remain symptomatic (Grade A)

##### *Evidence in CKD patients from randomised controlled trials*

There are no randomised controlled trials examining blockade of the renin angiotensin system specifically in patients with reduced kidney function *and* heart failure and hence the only evidence is from subgroup or post hoc analyses of other randomised controlled trials. Whilst trials have reported that reduced kidney function [4, 26], worsening kidney function [27] and proteinuria [28-30] are associated with increased mortality in patients with heart failure, few have actually reported the effect of the intervention in the patients with chronic kidney disease.

Of all the trials of drugs that inhibit the renin-angiotensin system, three reported subgroup analyses of patients with chronic kidney disease (Table 1). In one of the earliest studies of angiotensin-converting enzyme inhibitors in heart failure [31], patients with a serum creatinine above the median value of 123  $\mu\text{mol/L}$  who received enalapril had a six month cumulative mortality of 28% compared to 55% in patients receiving placebo ( $p=0.004$ ) [32]. Crude mortality was reported in a separate publication [33]. In patients with reduced left ventricular ejection fraction following myocardial infarction in the Survival and Ventricular Enlargement (SAVE) Study [34],

mortality was reduced by treatment with captopril compared to placebo by 28% (95% confidence interval 6-45) in patients with GFR<60mL/minute. Cardiovascular mortality and morbidity was reduced by 31% (14-45) in this subgroup, and there was no significant interaction between effect of captopril and level of kidney function. Whilst the relative benefit was similar, the absolute benefit of treatment with captopril was greater in patients with GFR<60mL/minute. In patients with heart failure randomised to the angiotensin receptor blocker valsartan or placebo, 58% had a GFR below 60mL/minute at baseline [30]. This subgroup received no mortality benefit but there was a significant reduction in first morbid event with valsartan treatment (hazard ratio 0.86, 0.74-0.99). The interaction term was not significant.

In a combined analysis of studies of candesartan in heart failure patients, 36% of participants analysed had a GFR below 60mL/minute [4]. Lower GFR was strongly associated with cardiovascular mortality and heart failure hospitalisation. Whilst outcome by treatment assignment was not specifically reported, the authors reported no interaction between treatment effect of candesartan and level of GFR ( $p$  for interaction=0.88). Although the various CHARM studies performed subgroup analyses of a number of pre-specified subgroups, level of kidney function was not one of them [35-37].

A limitation of applying results of these subgroup or post hoc analyses is that the definition of CKD was based on a single serum creatinine measurement to estimate GFR and not two measurements three months apart that would ensure the participant has *chronic* kidney disease. Furthermore, the mode of action of blockers of the renin-angiotensin system may in itself result in a rise in serum creatinine that does not of itself represent kidney disease.

#### *Results of other studies*

Some studies in different CKD populations have demonstrated that blockade of the renin-angiotensin system reduces de novo heart failure in patients without known heart failure at baseline. The E-COST Study randomised 141 non-diabetic hypertensive patients age 60-75 years with creatinine between 106 and 177  $\mu\text{mol/L}$  to open-label candesartan or conventional therapy [38]. In the 71 patients with pre-existing cardiovascular disease, combined cardiovascular events were reduced, mainly because heart failure occurred in 4/33 treated with candesartan compared to 13/38 treated with conventional therapy. These events were not clearly defined and not adjudicated in a blind fashion.

In a randomised controlled trial of the angiotensin receptor blocker losartan in patients with diabetic nephropathy (RENAAL), first hospitalisation for heart failure was a pre-specified and adjudicated secondary endpoint [39]. Patients treated with losartan had a 32% reduction in risk of first hospitalisation for heart failure from 16.7% to 11.9% ( $p=0.005$ ). Similarly, in a randomised controlled trial comparing irbesartan to placebo or amlodipine in patients with diabetic nephropathy (IDNT), patients receiving irbesartan had a lower incidence of the secondary adjudicated outcome of first congestive heart failure episode compared to the other two groups [40]. In contrast, ramipril did not reduce the incidence of heart failure in patients with diabetes and microalbuminuria or proteinuria compared to placebo in another large randomised controlled trial [41]. These patients had lower serum creatinine than the RENAAL and IDNT patients.

### *Adverse effects*

One of the potential limiting factors to the therapeutic blockade of the renin-angiotensin system in patients with CKD is concern regarding adverse effects. In the Survival and Ventricular Enlargement (SAVE) Study, 12% of participants developed worsening of kidney function defined by a rise in serum creatinine of  $23\mu\text{mol/L}$ , but there was no difference between those receiving captopril or placebo [27]. The Assessment of Lisinopril and Survival (ATLAS) Study compared low dose to high dose lisinopril in patients with heart failure and reported on adverse events in patients with a serum creatinine above or below  $132.6\mu\text{mol/L}$  [42]. In the group receiving high dose lisinopril, 3.7% of patients with creatinine  $\geq 132.6\mu\text{mol/L}$  withdrew due to episodes of hypotension or dizziness compared 1.0% in the group with a serum creatinine below this level. For the outcome of renal dysfunction or hyperkalaemia, the corresponding proportions were 6.0% compared to 0.8%, respectively. Whilst there was a relative increase in these adverse events in patients with reduced kidney function, the authors concluded that high doses are well tolerated in most patients. The statistical or clinical significance of these differences in proportions, or relative risks, were not reported. The Evaluation of Losartan in the Elderly (ELITE) Study compared losartan to captopril in patients with heart failure aged 65 years or more, and the primary endpoint of this tolerability study was a persisting rise in serum creatinine of  $\geq 26.5\mu\text{mol/L}$  [43]. Patients had a mean ( $\pm$  standard deviation) serum creatinine of  $106\pm 35\mu\text{mol/L}$  but a specific subgroup with reduced kidney function was not reported. There was no difference between groups, with 10.5% of patients reaching this primary endpoint in each group, although 32% of participants with an initial rise in serum creatinine did not have a confirmatory measure performed.

### *Summary*

In patients with heart failure, post hoc analyses of two trials suggest that patients with CKD receive the same, or possibly greater, reduction in mortality with an angiotensin-converting enzyme inhibitor. One post hoc analysis demonstrated no benefit when an angiotensin receptor blocker was compared to placebo. The reported increase in adverse effects in patients with reduced kidney function suggests careful monitoring is required but does not justify withholding this treatment.

## **2. Beta-blocker therapy**

### *Evidence from studies of patients without CKD*

In patients with heart failure, therapy with one of three beta-blockers receives the strongest recommendation (Class I) based on the highest level of evidence (Level A) [20]. This is because this therapy reduces mortality by 35% and the number needed to treat for one year to prevent one death is only 20 [44].

### *National Heart Foundation guideline for the general population:*

- Beta-blockers are recommended for patients with systolic heart failure on appropriate doses of ACE inhibitor (Grade A), including patients with advanced heart failure (Grade B)

### *Evidence in CKD patients from randomised controlled trials*

There are no randomised controlled trials that specifically recruited patients with CKD, but five trials report post hoc subgroup analyses of patients with glomerular filtration rate (or creatinine clearance) less than  $60\text{mL/minute}$

**(Table 1).** These studies used bisoprolol (CIBIS II) [45], metoprolol succinate (MERIT HF) [46], nebivolol (SENIORS) [47], and carvedilol (two studies: CAPRICORN, COPERNICUS) [48]. These studies reported between 21 and 40% reduction in all-cause mortality with beta-blocker therapy that was statistically significant in three of the four reports. There was no significant interaction between beta-blocker therapy and level of kidney function for the mortality outcome in these studies. For the outcome of all-cause mortality combined with hospitalisation for worsening heart failure in MERIT-HF, the P for interaction of 0.011 suggested increasing benefit at lower GFR [46]. A systematic review of these studies demonstrated an overall 28% reduction in all-cause mortality with beta-blocker therapy in these trials with no evidence of any heterogeneity (Badve et al. JACC, in press).

*Results of other studies*

Not discussed.

*Adverse effects*

In MERIT HF, reported adverse events included cardiac failure, fatigue, bradycardia, dizziness and hypotension. In the metoprolol succinate group, the incidence of adverse events increased as the GFR declined, being 8.4 per 100 patient years, 13.6 and 16.9 for GFR>60 mL/minute, GFR 45-60 mL/minute and GFR<45 mL/minute, respectively [46]. In the systematic review, hypotension and bradycardia were five times more likely to occur in the patients randomised to beta-blocker therapy than placebo (Badve et al. JACC, in press).

*Summary*

The reduction in mortality achieved by therapy with four different beta-blockers in patients with heart failure is at least as much in patients with reduced kidney function as with normal kidney function. However, the majority of patients in these trials had CKD Stage III and the low number of patients with GFR<30mL/minute in these trials makes application of the results to these patients less certain.

### **3. Aldosterone antagonists**

*Evidence from studies of patients without CKD*

In patients with severe heart failure symptoms (New York Heart Association Class III or IV) or recently hospitalised with heart failure, the addition of the aldosterone antagonist spironolactone to an angiotensin-converting enzyme inhibitor, diuretics and digoxin reduced all-cause mortality by 30% and hospitalisation for heart failure by 35% over 2 years [49]. The proportion of patients receiving beta-blocking agents was 10-11% in this trial. In patients with acute myocardial infarction complicated by heart failure, the addition of the aldosterone antagonist eplerenone reduced all-cause mortality by 15% [50]. The proportion of patients receiving beta-blocking agents was 75% in this trial. These treatments are given a “Class I” recommendation in guidelines, provided that kidney function and serum potassium can be monitored [20]. In addition, the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) demonstrated a 37% reduction in cardiovascular death or first hospitalization for heart failure in patients with heart failure and mild symptoms (NYHA Class II), although the mean left ventricular ejection fraction was 26% [51].

*National Heart Foundation guideline for the general population:*

- Treatment with the aldosterone antagonist spironolactone is recommended for patients who remain severely symptomatic on appropriate doses of ACE inhibitor and diuretics (Grade B)
- Treatment with the aldosterone antagonist eplerenone is recommended for patients who remain mildly symptomatic on appropriate doses of ACE inhibitor and beta-blockers (Grade B), and in patients with left ventricular systolic dysfunction and symptoms of heart failure in the early post-myocardial infarction period (Grade B)

*Evidence in CKD patients from randomised controlled trials*

In the randomised controlled trials of more severe heart failure, a pre-specified subgroup analysis based on the serum creatinine was reported in the original publications [49, 50], but no post hoc analysis according to GFR has been reported. In the Randomised Aldactone Evaluation Study (RALES), the relative risk of all-cause mortality in patients with serum creatinine  $\geq 106 \mu\text{mol/L}$  receiving spironolactone was 0.8 (0.65-0.95) compared to placebo [49], and in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), the relative risk of all-cause mortality in patients with serum creatinine  $\geq 96 \mu\text{mol/L}$  receiving eplerenone was 0.9 (0.8-1.1) compared to placebo [50]. In both studies, patients with higher serum creatinine derived less benefit from the aldosterone antagonist and in EPHESUS, a significant interaction was demonstrated ( $p=0.03$ ) between serum creatinine and treatment assignment. Patients with reduced kidney function were at greater risk of hyperkalaemia, but it is not clear whether this group derived less benefit because of increased toxicity or because of other factors. In EMPHASIS-HF, benefit was similar in the one third of participants with a  $\text{GFR} < 60 \text{mL/minute}$  [51].

*Results of other studies*

One randomised controlled trial has been performed in patients with stage II and III chronic kidney disease that compared spironolactone to placebo and evaluated left ventricular mass and aortic stiffness [52]. These patients had preserved left ventricular ejection fraction and although this was not a heart failure trial, it did demonstrate a significant reduction in left ventricular mass index as well as measures of aortic stiffness. In an earlier cohort, these investigators demonstrated that these cardiac abnormalities are similar to that seen in patients with heart failure and preserved ejection fraction [53].

*Adverse effects*

The main adverse effects of spironolactone reported in RALES were breast pain or gynaecomastia in males (10% in the spironolactone group compared to 1% in the placebo group,  $p < 0.001$ ), and hyperkalaemia (serum potassium  $\geq 6.0 \text{mmol/L}$ ) occurred in 1-2% of participants and was no different between spironolactone and placebo [49]. In EPHESUS, where eplerenone was compared to placebo, gynaecomastia occurred in less than 1% of participants and did not differ by treatment assignment [50]. Hyperkalaemia (serum potassium  $\geq 6.0 \text{mmol/L}$ ) occurred in 5.5% of participants receiving eplerenone and 3.9% receiving placebo ( $p=0.002$ ). The proportion of participants who developed hyperkalaemia and were receiving eplerenone was 10.1% if creatinine clearance was less than  $50 \text{mL/minute}$ , compared to 4.6% if creatinine clearance was  $50 \text{mL/minute}$  or greater and by logistic regression, the risk of hyperkalaemia was significantly greater with lower baseline

kidney function. In EMPHASIS-HF, hyperkalaemia (not defined) was twice as frequent in the participants randomised to eplerenone (8%) compared to placebo (4%), but only 1% in each group actually discontinued therapy because of this. Episodes of renal failure were also similar between groups.

### *Summary*

Trials comparing aldosterone antagonism to placebo demonstrate unclear clinical benefit in patients with reduced kidney function and potentially greater toxicity. These agents should therefore be used with caution in such patients until more evidence becomes available.

## **4. Digoxin**

### *Evidence from studies of patients without CKD*

Treatment with digoxin in patients with heart failure had no effect on mortality but significantly reduced hospitalisations for heart failure, a secondary endpoint, by 28% in the large Digitalis Intervention Group Study [54]. These patients were receiving angiotensin converting enzyme inhibitors and diuretics, but not beta-blockers.

### *National Heart Foundation guideline for the general population:*

- Digoxin is considered a second line agent for patients with advanced heart failure to improve symptoms and reduce hospitalisations (Grade B)

### *Evidence in CKD patients from randomised controlled trials*

A post hoc analysis from the Digitalis Intervention Group Study analysed patients according to MDRD eGFR levels >60mL/minute per 1.73m<sup>2</sup> (n=3643), eGFR 30-60mL/minute per 1.73m<sup>2</sup> (n=2939) and eGFR<30ml/minute per 1.73m<sup>2</sup> (n=218) [55]. Although mortality increased as GFR declined, therapy with digoxin did not reduce mortality in the groups with GFR≤60mL/minute per 1.73m<sup>2</sup>, but did reduce the secondary outcome of all-cause mortality plus heart failure hospitalisation in patients with eGFR 30-60mL/minute per 1.73m<sup>2</sup> (hazard ratio for digoxin versus placebo 0.84, 0.76-0.93). An interaction between level of kidney function and effect of digoxin was not demonstrated (p=0.54 for interaction term).

### *Results of other studies*

No other randomised controlled trials of digoxin in patients with heart failure have either been performed in patients with chronic kidney disease or reported on a subgroup of patients with chronic kidney disease within a larger trial.

### *Adverse effects*

Patients with reduced kidney function received lower doses of digoxin, but attained higher levels. Adverse effects of digoxin were not reported in the subgroup analysis, and in the main trial, supraventricular arrhythmia and second or third degree atrioventricular block occurred 2 to 3-fold more frequently in participants on digoxin as compared to placebo [54]. A subsequent analysis of this trial examined the effect of hypokalaemia on outcomes [56]. Serum potassium was less than 4.0mmol/L in 19% of participants with eGFR<60mL/minute and compared to normokalaemia (4.0-4.9mmol/L), all-cause mortality and other adverse outcomes were significantly increased in participants with hypokalaemia. Randomisation to digoxin had no significant effect on this association.

### *Summary*

Digoxin may reduce a combined outcome of all-cause mortality and heart failure hospitalisation in patients with eGFR 30-60mL/minute, but the risk of adverse effects, particularly in patients with serum potassium <4mmol/L, should be carefully considered.

## **5. Erythropoiesis stimulating agents**

### *Evidence from studies of patients without CKD*

Just as heart failure and CKD are common co-morbidities, anaemia is also a common co-morbidity in both conditions. The risk of death increases as the number of these co-morbidities present increases [57]. In addition to possible benefits from raising haemoglobin, there are potential non-haemopoietic effects of erythropoiesis stimulating agents (ESA) that might benefit patients with heart failure, such as reducing cardiac myocyte apoptosis and fibrosis, and neovascularisation mediated by vascular endothelial growth factor [57]. Some investigators have suggested that anaemia should be corrected with available tools (erythropoiesis stimulating agents and iron supplementation) in patients with CKD and heart failure [58].

Only one trial is seeking to study the effects of treatment with an ESA in patients with co-morbid heart failure, CKD (GFR 20-70mL/minute) and mild anaemia (Clinical Trials.gov NCT00356733) [59]. However, clinical events will not be assessed.

### *National Heart Foundation guideline for the general population:*

- The possibility of anaemia correction with ESAs is acknowledged but no formal recommendation is made

In the absence of a specific randomised controlled trial, this guideline presents data from either randomised controlled trials in patients with heart failure and anaemia, in which data on a CKD subgroup was available, or data from randomised controlled trials in patients with CKD and anaemia, in which data on heart failure was available.

### *Evidence in CKD subgroups of randomised controlled trials designed specifically for heart failure patients*

A number of randomised controlled trials have been performed in patients with anaemia and heart failure. A meta-analysis of seven trials demonstrated no reduction in mortality with treatment with ESA but there was significantly reduced heart failure hospitalisation [60], and a separate meta-analysis of the same studies reported improved left ventricular ejection fraction and exercise capacity [61]. All but one of these trials was placebo-controlled. The mean baseline haemoglobin was above 10g/dL in these studies, and the mean baseline serum creatinine ranged from 115 $\mu$ L up to 221 $\mu$ mol/L, suggesting that CKD was prevalent in these patients. A large randomised controlled trial is underway to evaluate the effect of darbepoetin alfa compared to placebo on morbidity and mortality in heart failure patients with anaemia (Clinical Trials.gov NCT00358215) [62]. Patients with a serum creatinine greater than 265  $\mu$ mol/L will be excluded, but it is likely that there will be a substantial subgroup with CKD. It is hoped that the investigators will report on this subgroup.

### *Evidence in heart failure subgroups of randomised controlled trials designed specifically for CKD patients*

In contrast to the heart failure studies, the randomised controlled trials of erythropoiesis stimulating agents that have been performed in patients with CKD have predominantly compared high versus low haemoglobin targets, and only one is

placebo-controlled. Meta-analyses of these studies have been performed at strategic time points and point estimates for clinical outcomes such as mortality and vascular access thrombosis have consistently favoured the lower haemoglobin target groups [63-65]. Heart failure subgroups were not reported. The major trials of patients with CKD not requiring dialysis are presented below, with a focus on patients with heart failure.

The Canadian Multicentre Randomised Trial included 172 participants with a calculated creatinine clearance between 15-79mL/minute and randomised them to achieve a haemoglobin level of 120-140g/L or 90-115g/L using erythropoietin alfa [66]. Less than 10% of patients had symptomatic heart failure at baseline. Treating to higher haemoglobin had no benefit on the primary outcome of change in left ventricular mass index.

An Australian trial of similar design randomised 155 patients with calculated creatinine clearance of 15-50mL/minute to a haemoglobin target of 90-100g/L compared to 120-130g/L, maintained by treatment with erythropoietin alfa [67]. Patients with New York Heart Association (NYHA) grade III or IV heart failure were excluded and treatment did not affect the development of left ventricular hypertrophy.

A study that randomised 390 patients with an estimated glomerular filtration rate between 25 and 60mL/minute to high versus low haemoglobin targets, maintained with erythropoietin alfa was terminated prematurely by the sponsor because of the emerging concerns regarding pure red cell aplasia at that time [68]. The primary outcome was rate of GFR decline and patients with NYHA grade III or IV heart failure were excluded from this study.

A Scandinavian study that enrolled 416 participants included 72 patients with creatinine clearance less than 30mL/minute but not on dialysis (the rest of the participants were receiving dialysis) [69]. Only three of the 72 participants had heart failure and in response to the report of a study in patients undergoing dialysis [70], the protocol was amended to make NYHA grade III or IV heart failure an exclusion criterion.

The CREATE Study randomised 603 participants with an estimated glomerular filtration rate of 15-35mL/minute to high versus low haemoglobin targets with erythropoietin beta [71]. Congestive heart failure was an exclusion criteria but this was presumably only NYHA grade III or IV heart failure as patients with NYHA grade I or II heart failure made up 27% of participants who underwent a baseline echocardiogram in a subsequent report [72]. In the subgroup of patients with eccentric left ventricular hypertrophy, there were more cardiovascular events (including acute heart failure) at 4 years in patients randomised to the higher haemoglobin target compared to patients randomised to the lower haemoglobin target.

The CHOIR Study randomised 715 patients with an estimated glomerular filtration rate of 15-50mL/minute to achieve a haemoglobin of 113g/L (n=717) compared to 135g/L with erythropoietin alfa [73]. Congestive heart failure was present in 22.9% and 24.4% in these groups, respectively. The primary composite endpoint of death, myocardial infarction, hospitalisation for heart failure and stroke was increased in the high haemoglobin target group, and heart failure hospitalisation was the most

frequent component of this primary endpoint (45.5% of events). There was a significant interaction between treatment allocation and baseline history of heart failure in that treating to the higher haemoglobin target had no effect on the primary outcome in patients with a history of heart failure, but resulted in increased events in patients with no history of heart failure ( $p$  for interaction=0.028) [74].

The TREAT Study randomised 2012 patients with diabetes and an estimated glomerular filtration rate of 20-60mL/minute to darbepoetin alfa with target haemoglobin 130g/L, and 2026 to placebo with rescue darbepoetin alfa if the haemoglobin fell below 90g/L [75]. Heart failure was present at baseline in 31.5% and 35.2% in these groups, respectively ( $p=0.01$ ). There was no difference in the composite endpoint of death or non-fatal cardiovascular events, and no difference in each individual component of the primary event (including heart failure), except that the risk of stroke was almost two-fold higher in the patients receiving darbepoetin alfa. A subgroup analysis according to baseline heart failure was not reported.

#### *Results of other studies*

Other studies are not discussed.

#### *Adverse effects*

Potential adverse effects of therapy with erythropoiesis stimulating agents in patients with CKD and heart failure are those reported in the meta-analyses: hypertension, stroke, vascular access thrombosis. The risk of death, cardiovascular events and end-stage kidney disease was less in the low haemoglobin arms but these were not statistically significant [65].

#### *Summary*

Currently, there is no evidence that correcting anaemia in patients with CKD and heart failure reduces clinical events. Erythropoiesis stimulating agents should be used with caution in patients with both heart failure and CKD and the potential harms demonstrated in the CKD studies should be carefully weighed against the potential to ameliorate symptoms attributable to anaemia in the individual patient.

## **6. Diuretics to reduce extracellular fluid volume**

### *Evidence from studies of patients without CKD*

Diuretic therapy is important in the management of symptomatic patients with heart failure in order to control the extracellular fluid volume expansion and relieve pulmonary congestion. Randomised controlled evidence for alteration of disease progression is lacking [76].

The ALLHAT randomised controlled trial recruited patients aged 55 years or over with at least one cardiovascular risk factor but excluded patients with heart failure at baseline [77]. There were significantly less episodes of de novo fatal heart failure in patients randomised to the thiazide diuretic chlorthalidone compared to a calcium channel antagonist, angiotensin converting enzyme inhibitor or alpha-receptor blocker. When heart failure was divided into preserved ejection fraction and reduced ejection fraction, chlorthalidone was superior in all comparisons except when compared to the angiotensin converting enzyme inhibitor for the outcome of heart failure with reduced ejection fraction, where the therapies were equivalent [78]. In the Blood Pressure Lowering Trialist's Collaboration meta-analysis, diuretics were

combined with beta-blockers and this combination was no different to inhibition of the renin angiotensin system, but superior to calcium antagonists with respect to reducing heart failure hospitalisations [79]. There are no long-term randomised controlled trials of diuretic therapy with important clinical outcomes in heart failure patients and thus all guideline recommendations regarding diuretics are based upon the lowest levels of evidence [20, 22].

*National Heart Foundation guideline for the general population:*

- Diuretics are recommended to achieve euvolaemia but should not be considered as monotherapy in patients with systolic dysfunction (Grade D)

*Evidence in CKD patients from randomised controlled trials*

There is no evidence in this group.

*Results of other studies*

In patients with reduced kidney function, higher doses of loop diuretics are often required and thiazide diuretics are much less effective when the glomerular filtration rate falls below 30mL/minute [80].

*Adverse effects*

The main adverse effects of diuretic therapy are excessive volume depletion, leading to worsening kidney function and neurohormonal activation, and electrolyte abnormalities, such as hypokalaemia, hypomagnesaemia and hyponatraemia [20]. Accurate assessment of volume state is thus critical to effective use of diuretics and avoidance of these important adverse effects [81]. Idiosyncratic reactions can also occur.

*Summary*

Diuretic therapies are useful and necessary to treat states of volume excess, but there is no data in patients with CKD to either recommend them or discount them as a long term therapy to improve prognosis. Clinical volume state must be carefully monitored.

## **7. Implantable devices**

*Evidence from studies of patients without CKD*

Implantable cardioverter defibrillators (ICD) reduced mortality by 23% in patients with a previous episode of unprovoked ventricular arrhythmia, or with left ventricular ejection fraction less than 35% and NYHA Class II or III symptoms [82]. Similarly, cardiac resynchronisation therapy (CRT) reduced mortality plus hospital admission by 20% in patients with NYHA Class III or IV symptoms, an ejection fraction below 35%, and with a prolonged QRS ( $\geq 120$ ms) [83]. A meta-analysis of CRT studies

*National Heart Foundation guideline for the general population:*

- Implantable cardioverter defibrillators should be considered for patients with symptomatic heart failure (i.e. NYHA functional class II–III) and LVEF  $\leq 35\%$  (Grade A); other criteria are also listed in guidelines
- Cardiac resynchronisation therapy, with or without ICD, should be considered in patients with symptomatic heart failure (i.e. NYHA functional class II–IV) who meet specific criteria (Grade A); criteria listed in guidelines and update

*Evidence in CKD patients from randomised controlled trials*

Subgroups with chronic kidney disease were not reported in the above studies. The Multicentre Automatic Defibrillator Implantation Trial II demonstrated a 30% reduction in mortality in patients who had a left ventricular ejection fraction  $\leq 30\%$  within a month following a myocardial infarction [84]. These investigators subsequently examined three subgroups, one of which was blood urea nitrogen [85]. Although a measure of renal function, blood urea nitrogen was considered by these investigators as a measure of severity of heart failure and dichotomised at 25mg/dL (8.9mmol/L) based on previous data, and 30% of participants had blood urea nitrogen above this level. Mortality was greater in these patients, but there was no interaction between therapy with an ICD and level of blood urea nitrogen. A meta-analysis of CRT demonstrated a reduction in mortality of 17% in patients with NYHA Class I and II symptoms and 22% in patients with NYHA Class III and IV symptoms, but noted that there was insufficient data to examine a chronic kidney disease subgroup [86].

*Results of other studies*

A meta-analysis of observational studies has demonstrated that patients who receive an ICD have an approximately three-fold greater mortality if they have CKD compared to if they have better kidney function [87]. In a retrospective case control study that identified patients between 1998 and 2008, 33 patients had a left ventricular ejection fraction  $\leq 35\%$  and a GFR below 60mL/minute [88]. The two year survival of patients who received an ICD was 80%, compared to 61% in those who did not ( $p=0.027$ ). Another analysis divided 441 patients who had an ICD inserted between 1994 and 2002 according to their kidney function. Mean survival was 86 months, 60 months and 38 months for patients with  $GFR \geq 60$ mL/minute,  $GFR < 60$ mL/minute and patients receiving dialysis, respectively [89].

*Adverse effects*

Adverse effects of ICD have not been reported specifically in patients with CKD.

*Summary*

Studies of ICD and CRT have not been reported specifically in patients with CKD.

## Patients receiving dialysis

### 1. Blockade of the renin-angiotensin system

#### *Evidence from randomised controlled trials*

Four randomised controlled trials of blockade of the renin-angiotensin system in patients requiring dialysis have been published.

Cice et al randomised 332 haemodialysis patients at 30 centres to telmisartan or placebo [90]. All patients had dialysis four times a week and all received therapy with an ACE inhibitor. All had heart failure defined by NYHA Class II or III symptoms and a left ventricular ejection fraction  $\leq 40\%$ . Other therapies included carvedilol (60%) and digoxin (50%). The primary outcome of all-cause mortality occurred in 35.1% of participants receiving telmisartan after a median of 36 months compared to 54.4% receiving placebo ( $p < 0.001$ ), and the adjusted hazard ratio for this outcome was 0.51 (**Table 2**). Cardiovascular deaths and admissions for heart failure were also significantly reduced in patients receiving telmisartan.

Two other studies examined angiotensin receptor antagonists in patients undergoing dialysis, but heart failure was not an inclusion criteria. Suzuki et al randomised 366 patients on haemodialysis to open-label angiotensin receptor blocker or no therapy [91]. Approximately 15% of participants had heart failure at baseline and in this study. There was no difference in mortality but cardiovascular events were reduced by 49% and the most frequently reported component of this composite endpoint was heart failure. Although said to be defined by American College of Cardiology and American Heart Association guidelines, the adjudication of this outcome was not clear. Eighty patients receiving haemodialysis who did not have heart failure were randomised to candesartan or no therapy and followed for a mean of 19 months [92]. Few were on ACE inhibitors or beta-blockers. There were 17 cardiovascular events in the control group and 7 in the candesartan group. Eleven of the events in the control group were attributed to heart failure (presumably de novo). However, the sample size was small, events few in number and although endpoints were assessed blinded to treatment, the definition of heart failure admission described only NYHA classification and no other clinical features.

The ACE inhibitor fosinopril was compared to placebo in a study of 397 haemodialysis patients whose main entry criteria was left ventricular hypertrophy [93]. The proportion with heart failure at baseline was not reported and patients were followed for 24 months. There was no difference in the primary composite endpoint of cardiovascular events that included hospitalisation for heart failure between therapy with fosinopril and placebo.

An important limitation of these studies, particularly the ones that relied on admission for heart failure as an outcome is the difficulty in defining what constitutes an admission for heart failure in patients undergoing dialysis.

#### *Results of other studies*

The US Renal Data System (USRDS) Dialysis Morbidity and Mortality Study (DMMS) Wave 2 reported the effects of beta-blocking agents in patients on dialysis who commenced dialysis in 1996 [94]. In this cohort, between 21 and 26% of participants was receiving ACE inhibitor therapy, and the use of ACE inhibitors did not reduce either time to de novo heart failure, or time to a composite of de novo heart failure or death in the Cox regression models reported. In an earlier analysis that examined

hospitalisation for heart failure, ACE inhibitors were included but not retained in multivariable models with hospitalisation for heart failure as the outcome [95]. In a single centre analysis of 126 patients on haemodialysis, the use of ACE inhibitors was associated with improved survival and this effect was essentially confined to the patients under the age of 65 years [96]. Heart failure was reported in 35% of this cohort at baseline.

The most beneficial effect in observational studies appears to be with the use of ACE inhibitors following myocardial infarction. Using data from a national database of acute myocardial infarction, the Cooperative Cardiovascular Project demonstrated in patients with end-stage kidney disease that the in-hospital mortality of patients considered “ideal” for receiving an ACE inhibitor was 17.9% in patients who received an ACE inhibitor compared to 33.6% in those who did not ( $P=0.007$ ) [97]. Heart failure was present in 40% at baseline and the main criteria, other than contraindications, for being considered an “ideal” ACE inhibitor candidate was a left ventricular ejection fraction less than 40%. An analysis of 368 patients with end-stage kidney disease treated in a single coronary care unit from 1990-1998 compared patients prescribed an ACE inhibitor to those not prescribed an ACE inhibitor [98]. Heart failure was diagnosed in 69% of patients prescribed an ACE inhibitor and 47% of patients not prescribed an ACE inhibitor and treatment with an ACE inhibitor was associated with a 37% reduction in mortality over more than 5 years of follow up. Although supportive of a role for ACE inhibitors in this clinical setting in patients with end-stage kidney disease, these studies were not specifically in patients with heart failure and the observational nature of these studies makes them prone to sources of bias such as confounding by indication.

#### *Adverse effects*

In the study of telmisartan versus placebo in patients with heart failure already receiving an ACE inhibitor, 19 patients failed the run-in and this was because of hypotension in 7 [90]. Discontinuation of study drug occurred in 27 (16.3%) of patients receiving telmisartan compared to 18 (10.7%) receiving placebo ( $p<0.01$ ), with hypotension being the predominant reason in both groups. Hypotension was more common in participants receiving telmisartan.

#### *Summary*

There are no randomised controlled trials comparing ACE inhibitor or angiotensin receptor antagonists to placebo in patients receiving dialysis who have heart failure. Angiotensin receptor antagonist added to an ACE inhibitor appeared to reduce mortality compared to placebo in one trial of patients receiving dialysis who have heart failure.

## **2. Beta-blocker therapy**

### *Evidence from randomised controlled trials*

One randomised controlled trial of beta-blocker therapy in patients receiving dialysis who have heart failure has been published. This study randomised 114 patients with symptomatic heart failure (NYHA II or III) and a left ventricular ejection fraction  $<35\%$ . All patients were receiving either an ACE inhibitor (96.9%) or angiotensin receptor blocker (3.1%), all were receiving digoxin and all were receiving dialysis 4 times per week. The first report of this study reported an improvement in ejection fraction at 12 months from 26% to 36% in the patients receiving carvedilol compared to no improvement in the placebo arm [99]. During this phase of the study, participants,

investigators and outcome assessors were blinded to treatment allocation. These investigators subsequently reported mortality and cardiovascular events after a further 12 months in which blinding was not maintained [100]. In this analysis, all-cause mortality was reduced by 49% (hazard ratio 0.51, 95% confidence interval 0.32-0.82) and hospitalisation for heart failure by 81% (hazard ratio 0.19, 95% confidence interval 0.09-0.41). These were secondary endpoints in this study, and how the outcomes were adjudicated was unclear. It is interesting to note that there were only 3 deaths reported in the first 12 months, and then 71 deaths after 24 months.

#### *Results of other studies*

In observational data, beta-blockers do reduce mortality in patients with end-stage kidney disease although there are few studies specific to patients with heart failure. In the Cooperative Cardiovascular Project, patients considered “ideal” for a beta-blocker, essentially those without a contra-indication, the 30-day mortality following myocardial infarction was 20.7% in those receiving a beta-blocker compared to 31.2% in those not prescribed a beta-blocker ( $P < 0.001$ ) [97]. Heart failure was present in 40% of these patients at baseline. In the USRDS DMMS Wave 2 cohort patients without heart failure at baseline who received beta-blockers had a reduced risk of de novo heart failure (hazard ratio 0.69, 95% confidence interval 0.52-0.91) and composite of de novo heart failure and cardiac death (hazard ratio 0.77, 95% confidence interval 0.61-0.97). However, patients with heart failure at baseline who were receiving beta-blockers had no reduction in recurrent heart failure or mortality.

#### *Adverse effects*

Permanent treatment withdrawal was similar between carvedilol and placebo groups in Cice’s study [100]. Eighteen of an initial 132 patients were excluded in the run-in phase predominantly due to predictable side effects such as hypotension, bradycardia, worsening heart failure and bronchospasm.

#### *Summary*

The reduction in mortality and other events achieved by therapy with carvedilol in the sole study of beta-blocker therapy in patients requiring dialysis who have heart failure is impressive, but limitations such as small sample size and lack of blinding in the second 12 months indicate that a larger trial is required to confirm these results. However, this is consistent with reports of CKD subgroups in heart failure trials (Badve et al. JACC, in press).

### **3. Aldosterone antagonists**

#### *Evidence from randomised controlled trial subgroup or post hoc analyses in heart failure populations*

Most studies of aldosterone antagonism in patients undergoing haemodialysis examined safety, particularly in relation to hyperkalaemia.[101]. Sixteen patients receiving haemodialysis with heart failure (NYHA Class II or IV symptoms and a mean left ventricular ejection fraction between 31 and 34%) were randomised to spironolactone or placebo [102]. Left ventricular ejection fraction increased by 6% in patients receiving spironolactone compared to 0.8 in the placebo group ( $p = 0.046$ ), there was a significant reduction in cardiovascular hospitalisations in the spironolactone group but an increase in admissions for infections.

*Results of other studies*

A study of 108 patients undergoing haemodialysis who had LVH on echocardiogram and BNP>200pg/mL randomised participants to carvedilol and spironolactone in a 2x2 factorial design (Nakao N, Hasegawa H, Fujimori A, Seno H, Toriyama T, Kawahara H. Effects of Combined B-blockade and anti-aldosterone antagonist treatment for cardiovascular prevention in patients receiving maintenance dialysis. J Am Soc Nephrol S 2007; 18:709A). Patients with severe heart failure (NYHA Class IV) were excluded. The mean left ventricular ejection fraction was over 50% in these patients. Whilst there may have been a benefit from the combination of carvedilol and spironolactone in reducing cardiac events compared to monotherapy, no benefit of spironolactone monotherapy was demonstrated. One patient developed hyperkalaemia that required treatment.

*Adverse effects*

An uncontrolled study of 50 haemodialysis patients demonstrated that spironolactone 25mg daily could be administered to patients undergoing haemodialysis without severe hyperkalaemia (K>6.8mmol/L) [103]. Three of 50 participants withdrew due to gynaecomastia.

*Summary*

Aldosterone antagonism at doses equivalent to spironolactone 25 mg daily may be prescribed for patients undergoing dialysis where potassium is closely monitored. Severe hyperkalaemia is a rare event in the studies to date. Evidence of clinical benefit is lacking.

#### **4. Digoxin**

*Evidence from randomised controlled trial subgroup or post hoc analyses in heart failure populations*

There are no randomised controlled trials or post hoc analyses examining the use of digoxin in patients undergoing dialysis who have heart failure.

*Results of other studies*

A very large retrospective cohort study from Fresenius Medical Care North America analysed outcomes in patients receiving digoxin and adjusted for co-morbidities using propensity score analysis [104]. Patients receiving digoxin who had coexistent heart failure had an 18% increased risk of mortality, even after adjustment for other covariates and the propensity score. This risk was similar if they had co-existing atrial fibrillation. Furthermore, high serum levels of digoxin, and low pre-dialysis serum potassium levels were also associated with greater mortality.

*Adverse effects*

Specific adverse effects were not analysed in the Fresenius Medical Care North America study.

*Summary*

There is no evidence of benefit of digoxin in patients receiving dialysis who have heart failure, and a non-randomised analysis suggests significant harm. If digoxin is used in such patients, careful monitoring of serum potassium in peritoneal dialysis patients and careful attention the potassium concentration of the dialysate in haemodialysis patients is necessary to avoid hypokalaemia.

## **5. Erythropoiesis stimulating agents**

### *Evidence from randomised controlled trials*

A number of randomised controlled trials of ESAs enrolled patients undergoing dialysis with heart failure or ischaemic heart disease, but none were exclusively in patients with heart failure. All compared different haemoglobin targets and none randomised patients to ESA versus placebo.

In the most recent meta-analysis of ESAs in patients with chronic kidney disease, including those undergoing dialysis, higher haemoglobin targets were associated with a significantly increased risk of stroke, hypertension and vascular access thrombosis, and an increased risk of mortality that was not statistically significant [65]. No interaction was demonstrated between patients with CKD not requiring dialysis and those requiring dialysis for these outcomes (except the vascular access thrombosis). The largest and most relevant RCT (n=1233) enrolled patients with either heart failure or ischaemic heart disease who were undergoing haemodialysis and the Data Monitoring Committee recommended that the trial be stopped after the third interim analysis [70]. The risk of death or non-fatal myocardial infarction was increased in patients randomised to a haematocrit of 42% compared to 30% (risk ratio 1.3, 95% confidence interval 0.9-1.9). The incidence of vascular access thrombosis was 39% in the high haematocrit group compared to 29% in the low haematocrit group (p=0.001). A sub-study of 28 participants of this trial from one centre demonstrated no difference in ambulatory blood pressure between the two groups, although may have been subject to Type II error [105]. A study of 146 patients with either left ventricular concentric hypertrophy or dilatation, 76 of whom had left ventricular dilatation, were randomised to achieve a haemoglobin target of 10g/dL compared to 13.5g/dL using epoetin  $\alpha$  and changes in left ventricular parameters were measured [106]. Left ventricular cavity volume index was not different between the groups after 48 weeks.

### *Results of other studies*

In early observational data of patients with mean haemoglobin of 8.8g/dL, lower haemoglobin was associated with an increased risk of de novo and recurrent heart failure, independent of age, diabetes and ischaemic heart disease [107].

### *Adverse effects*

Similar adverse effects were seen with high haemoglobin targets – an increase in the risk of death and non-fatal myocardial infarction that did not reach statistical significance, and an increase in vascular access thrombosis.

### *Summary*

Despite early observational data that anaemia is significantly associated with heart failure, there is no evidence that correction of anaemia reduces heart failure events and there is some evidence of harm.

## **6. Diuretics to reduce extracellular fluid volume**

There are no randomised controlled trials of the use of diuretics in patients requiring dialysis for the treatment of heart failure.

## **7. Implantable devices**

### *Evidence from randomised controlled trials*

There are no randomised controlled trials specifically in patients undergoing dialysis. A randomised controlled trial is underway in the Netherlands to randomise patients undergoing dialysis aged 55 to 80 to ICD therapy or not [108]. In the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial (ISRCTN20479861), heart failure is not a specific inclusion criteria and NYHA Class IV heart failure is an exclusion criteria. This trial is scheduled to finish in 2012.

#### *Results of other studies*

Some observational studies demonstrate benefit of ICD therapy in primary prevention in patients with LVEF<35%, as well as in secondary prevention in patients who have survived a cardiac arrest or ventricular tachyarrhythmia.

Patients undergoing dialysis who received an ICD in one centre over a 14 year period (n=50) were compared to contemporaneous patients receiving dialysis at another centre who had a LVEF<35% (n=50), the most common indication for receiving an ICD. Forty-three patients received the ICD based on their LVEF (“primary prevention”), and 7 received the ICD following cardiac arrest or syncope (“secondary prevention”) [109]. The median survival was 8 years with an ICD versus 2.5 years without and the hazard ratio adjusted for beta-blocker and amiodarone use (which were both greater in the ICD group) and other things demonstrated a 60% reduction in mortality with an ICD (hazard ratio 0.40; 95% confidence interval 0.19-0.82, p=0.01). However, this analysis may be subject to considerable residual confounding. In a retrospective analysis from a single centre that compared 31 patients receiving dialysis who had a LVEF<35% who did not receive an ICD to patients who did and demonstrated no difference in survival by ICD status [88].

In an analysis of the United States Medicare database, 30,518 patients receiving dialysis had a cardiac arrest or ventricular tachyarrhythmia between 1996 and 2001, but only 6,042 were still alive 30 days after the index event [110]. On year survival was 71% in the 460 patients who received an ICD (7.6%) compared to 49% in patients who did not receive an ICD. The association with survival was the same across tertiles of propensity scores.

Because ICD therapy comes with a considerable cost, some authors question the wisdom of treating patients with an ICD if such a therapy might be futile in the context of their overall risk of death [111]. In support of this argument, comparison of patients with ICD who are, or are not, receiving dialysis has been performed. A meta-analysis of such studies identified 89 patients receiving dialysis from 7 studies of 2,516 patients who received an ICD [112]. Despite the ICD, mortality was 2 to 3-fold greater in patients undergoing dialysis.

#### *Adverse effects*

Adverse effects of ICD in patients undergoing dialysis have not been reported in randomised controlled trials. In an observational study, there were more major complications in patients undergoing dialysis compared to patients not undergoing dialysis [113]. Importantly, 4 of 41 patients receiving dialysis had thrombosis of vascular access veins ipsilateral to the device.

#### *Summary*

The use of ICD therapy in patients receiving dialysis who have heart failure cannot be routinely recommended and consideration should be given to balance the

potential benefit to the individual patient where this benefit may be less than that of someone not requiring dialysis, with the heightened risk of complications, particularly thrombosis of vascular access veins if the ICD is implanted on the same side as the vascular access.

CONSULTATION DRAFT

## **INTERNATIONAL GUIDELINES:**

### **Kidney Disease Outcomes Quality Initiative**

This guideline addresses “Cardiomyopathy (Systolic or diastolic dysfunction)” with regards to both diagnosis and management. This guideline recommends “maintenance of euvolaemia” as the cornerstone of therapy, and that treatment should be similar to the non-dialysis population with the exception that dosing schedules may need to be modified in haemodialysis. They suggest beta-blocking agents are preferred based on data that is “moderately strong” (the single carvedilol study), that ACE inhibitors be used although the data is “weak”, and that digitalis be considered as third line therapy (no data referred to). They also recommend that aldosterone antagonists be used with “great caution, or not at all” (based on “weak” data). (KDOQI CVD Guidelines, AJKD 2005)

### **UK Renal Association:**

No guideline addressing heart failure (Nephron Clin Pract 2011; 118(suppl 1)).

### **Canadian Society of Nephrology:**

### **European Best Practice Guidelines:**

## **Implementation and audit**

## **Suggestions for future research**

- 1.
- 2.

## References

1. Schrier RW: Role of Diminished Renal Function in Cardiovascular Mortality: Marker or Pathogenetic Factor? *Journal of the American College of Cardiology* 47:1-8, 2006
2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. *J Am Coll Cardiol* 52:1527-1539, 2008
3. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI: Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. *Clin J Am Soc Nephrol* 4:1302-1311, 2009
4. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. *Circulation* 113:671-678, 2006
5. Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation* 102:203-210, 2000
6. Levin A, Foley RN: Cardiovascular disease in chronic renal insufficiency. *Am J Kidney Dis* 36:S24-30, 2000
7. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. *Kidney Int* 47:884-890, 1995
8. Banerjee D, Ma JZ, Collins AJ, Herzog CA: Long-Term Survival of Incident Hemodialysis Patients Who Are Hospitalized for Congestive Heart Failure, Pulmonary Edema, or Fluid Overload. *Clin J Am Soc Nephrol* 2:1186-1190, 2007
9. Siedlecki A, Foushee M, Curtis JJ, Gaston RS, Perry G, Iskandrian AE, de Mattos AM: The impact of left ventricular systolic dysfunction on survival after renal transplantation. *Transplantation* 84:1610-1617, 2007
10. Lentine KL, Schnitzler MA, Abbott KC, Li L, Burroughs TE, Irish W, Brennan DC: De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. *Am J Kidney Dis* 46:720-733, 2005
11. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. *J Am Soc Nephrol* 13:1084-1090, 2002
12. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C, Papadimitriou J, Brisco MA, Blahut S: Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. *J Am Coll Cardiol* 45:1051-1060, 2005
13. Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD: Impact of renal transplantation on uremic cardiomyopathy. *Transplantation* 60:908-914, 1995
14. Casas-Aparicio G, Castillo-Martinez L, Orea-Tejeda A, Abasta-Jimenez M, Keirns-Davies C, Rebollar-Gonzalez V: The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension. *Transplant* 42:3524-3528, 2010

15. Rakhit DJ, Zhang XH, Leano R, Armstrong KA, Isbel NM, Marwick TH: Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease. *Am Heart J* 153:656-664, 2007
16. Bialostozky D, Leyva M, Villarreal T, Casanova JM, Perez-Grovas H, Lemus P, Jimenez G, Vallejo E, Jimenez-Angeles L, Herrera J, Altamirano J: Myocardial perfusion and ventricular function assessed by SPECT and Gated-SPECT in end-stage renal disease patients before and after renal transplant. *Arch Med Res* 38:227-233, 2007
17. Iqbal MM, Rashid HU, Banerjee SK, Rahman MH, Mohsin M: Changes in cardiac parameters of renal allograft recipients: a compilation of clinical, laboratory, and echocardiographic observations. *Transplant Proc* 40:2327-2329, 2008
18. van Duijnhoven EC, Cheriex EC, Tordoir JH, Kooman JP, van Hooff JP: Effect of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients. *Nephrol Dial Transplant* 16:368-372, 2001
19. Stern AB, Klemmer PJ: High-output heart failure secondary to arteriovenous fistula. *Hemodial Int* 15:104-107, 2011
20. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation* 119:e391-479, 2009
21. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ: 2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. *Med J Aust* 194:405-409, 2011
22. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL: Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. *Med J Aust* 185:549-557, 2006
23. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet* 355:1575-1581, 2000
24. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR: Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med* 141:693-704, 2004
25. Jong P, Demers C, McKelvie RS, Liu PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. *J Am Coll Cardiol* 39:463-470, 2002
26. Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. *N Engl J Med* 351:1285-1295, 2004
27. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD: Increase in creatinine and cardiovascular risk in

- patients with systolic dysfunction after myocardial infarction. *J Am Soc Nephrol* 17:2886-2891, 2006
28. Jose P, Tomson C, Skali H, Rouleau J, Braunwald E, Arnold JM, Cuddy T, Sussex B, Bernstein V, Pfeffer M, Solomon S: Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. *J Am Coll Cardiol* 47:1725-1727, 2006
  29. Capes SE, Gerstein HC, Negassa A, Yusuf S: Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. *Diabetes Care* 23:377-380, 2000
  30. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN: Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. *Circulation* 120:1577-1584, 2009
  31. The CONSENSUS Trial Study Group: Effects of Enalapril on Mortality in Severe Congestive Heart Failure. *New Engl J Med* 316:1429-1435, 1987
  32. Swedberg K, Eneroth P, Kjekshus J, Snapinn S: Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. *Am J Cardiol* 66:40D-44D, 1990
  33. Swedberg K, Kjekshus J: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *Am J Cardiol* 62:60A-66A, 1988
  34. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moye LA, Pfeffer MA, Solomon SD: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. *Circulation* 110:3667-3673, 2004
  35. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K: Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. *Circulation* 110:2618-2626, 2004
  36. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 362:759-766, 2003
  37. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet* 362:767-771, 2003
  38. Nakamura T, Kanno Y, Takenaka T, Suzuki H: An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. *Hypertens Res* 28:415-423, 2005
  39. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345:861-869, 2001
  40. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM,

- 
- Locatelli F, Goldhaber SZ, Lewis EJ: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. *Ann Intern Med* 138:542-549, 2003
41. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P: Development of Congestive Heart Failure in Type 2 Diabetic Patients With Microalbuminuria or Proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. *Diabetes Care* 26:855-860, 2003
42. Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Ryden L: Tolerant of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. *Arch Intern Med* 161:165-171, 2001
43. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snively DB, Chang PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 349:747-752, 1997
44. Shibata MC, Flather MD, Wang D: Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. *Eur J Heart Fail* 3:351-357, 2001
45. Erdmann E, Lechat P, Verkenne P, Wiemann H: Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. *Eur J Heart Fail* 3:469-479, 2001
46. Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson A, Johansson P, Kjekshus J, Ohlsson L, Samuelsson O, Waagstein F, Wedel H: The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). *J Card Fail* 15:310-318, 2009
47. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Bohm M, Coats AJ, Roughton M, Poole-Wilson P, Tavazzi L, Flather M: Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. *Eur J Heart Fail* 11:872-880, 2009
48. Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK: Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. *Circ Heart Fail* 4:18-26, 2011
49. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 341:709-717, 1999
50. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 348:1309-1321, 2003
51. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E-HS: Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 364:11-21, 2011
52. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN: Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. *Journal of the American College of Cardiology* 54:505-512, 2009
-

53. Edwards NC, Ferro CJ, Townend JN, Steeds RP: Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. *Heart* 94:1038-1043, 2008
54. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure: The Digitalis Investigation Group. *N Engl J Med* 336:525-533, 1997
55. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM: Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial. *J Am Soc Nephrol* 15:2195-2203, 2004
56. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A: Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease. *Circ Heart Fail* 3:253-260, 2010
57. Sandhu A, Soman S, Hudson M, Besarab A: Managing anemia in patients with chronic heart failure: what do we know? *Vasc Health Risk Manag* 6:237-252, 2010
58. Silverberg DS, Wexler D, Iaina A, Schwartz D: The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. *Clin Exp Nephrol* 13:101-106, 2009
59. van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, Cramer MJ, Velthuis BK, Meiss L, Kraaijenhagen RJ, Doevendans PA, Braam B, Gaillard CA: Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. *J Nephrol* Epub April 9, 2010
60. van der Meer P, Groenveld HF, Januzzi JL, Jr., van Veldhuisen DJ: Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. *Heart* 95:1309-1314, 2009
61. Jin B, Luo X, Lin H, Li J, Shi H: A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure. *Eur J Heart Fail* 12:249-253, 2010
62. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB: Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. *Eur J Heart Fail* 11:795-801, 2009
63. Strippoli GFM, Craig JC, Manno C, Schena FP: Hemoglobin Targets for the Anemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials. *J Am Soc Nephrol* 15:3154-3165, 2004
64. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. *Lancet* 369:381-388, 2007
65. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF: Systematic Review: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. *Ann Intern Med* Epub May 3, 2010
66. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgyamar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. *Am J Kidney Dis* 46:799-811, 2005

67. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of Early and Late Intervention with Epoetin alpha on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial. *J Am Soc Nephrol* 15:148-156, 2004
68. Rossert J, Levin A, Roger SD, Horl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM: Effect of early correction of anemia on the progression of CKD. *Am J Kidney Dis* 47:738-750, 2006
69. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. *Nephrol Dial Transplant* 18:353-361, 2003
70. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin. *N Engl J Med* 339:584-590, 1998
71. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 355:2071-2084, 2006
72. Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, Zaug MF, Burger HU, Drueke TB: Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. *J Am Soc Nephrol* 20:2651-2660, 2009
73. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 355:2085-2098, 2006
74. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK: A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. *Kidney Int* 77:239-246, 2010
75. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med* 361:2019-2032, 2009
76. Kazory A, Ross EA: Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. *Circulation* 117:975-983, 2008
77. Wright JT, Jr., Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH: ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. *Arch Intern Med* 169:832-842, 2009
78. Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S: Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *Circulation* 118:2259-2267, 2008
79. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 362:1527-1535, 2003

80. Ravnan SL, Deedwania PC: The rational use of diuretics in heart failure. *Curr Cardiol Rep* 5:237-242, 2003
81. Longhini C, Molino C, Fabbian F: Cardiorenal syndrome: still not a defined entity. *Clin Exp Nephrol* 14:12-21, 2010
82. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH: Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. *N Engl J Med* 352:225-237, 2005
83. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 350:2140-2150, 2004
84. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 346:877-883, 2002
85. Zareba W, Piotrowicz K, McNitt S, Moss AJ: Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). *Am J Cardiol* 95:1487-1491, 2005
86. Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA: Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. *Ann Intern Med* 154:401-412, 2011
87. Korantzopoulos P, Liu T, Li L, Goudevenos JA, Li G: Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. *Europace* 11:1469-1475, 2009
88. Khan F, Adelstein E, Saba S: Implantable cardioverter defibrillators confer survival benefit in patients with renal insufficiency but not in dialysis-dependent patients. *J Interv Card Electrophysiol* 28:117-123, 2010
89. Cheema A, Singh T, Kanwar M, Chilukuri K, Maria V, Saleem F, Johnson K, Frank J, Pires L, Hassan S: Chronic kidney disease and mortality in implantable cardioverter-defibrillator recipients. *Cardiol* epub, 2010
90. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, Calabro R: Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. *J Am Coll Cardiol* 56:1701-1708, 2010
91. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. *Am J Kidney Dis* 52:501-506, 2008
92. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y: Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. *Nephrol. Dial. Transplant.* 21:2507-2512, 2006
93. Zannad F, Kessler M, Leheret P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fasinopril and implications for future studies. *Kidney Int* 70:1318-1324, 2006
94. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL: Beta-Blocker Use in Long-term Dialysis Patients: Association With Hospitalized Heart Failure and Mortality. *Arch Intern Med* 164:2465-2471, 2004

95. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC: Heart failure as a cause for hospitalization in chronic dialysis patients. *Am J Kidney Dis* 41:1267-1277, 2003
96. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J: ACE inhibitors and survival of hemodialysis patients. *Am J Kidney Dis* 40:1023-1029, 2002
97. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. *J Am Coll Cardiol* 42:201-208, 2003
98. McCullough PA, Sandberg KR, Yee J, Hudson MP: Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. *J Renin Angiotensin Aldosterone Syst* 3:188-191, 2002
99. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A: Dilated cardiomyopathy in dialysis patients - beneficial effects of carvedilol: a double-blind, placebo-controlled trial. *J Am Coll Cardiol* 37:407-411, 2001
100. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. *J Am Coll Cardiol* 41:1438-1444, 2003
101. Chua D, Lo A, Lo C: Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? *Clin Cardiol* 33:604-608, 2010
102. Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, Eshaghian A, Ghassami M: Spironolactone in chronic hemodialysis patients improves cardiac function. *Saudi J Kidney Dis Transpl* 20:392-397, 2009
103. Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H, Ohmura H, Shio N: Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. *Cardiology* 114:32-38, 2009
104. Chan KE, Lazarus JM, Hakim RM: Digoxin Associates with Mortality in ESRD. *J Am Soc Nephrol* 21:1550-1559, 2010
105. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC: Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. *Kidney Int* 56:253-260, 1999
106. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. *Kidney Int* 58:1325-1335, 2000
107. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. *Am J Kidney Dis* 28:53-61, 1996
108. de Bie MK, Lekkerkerker JC, van Dam B, Gaasbeek A, van Buren M, Putter H, van Erven L, Bax JJ, Schalij MJ, Rabelink TJ, Jukema JW: Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial--a prospective pilot study. *Curr Med Res Opin* 24:2151-2157, 2008
109. Hiremath S, Punnam SR, Brar SS, Goyal SK, Gardiner JC, Shah AJ, Thakur RK: Implantable Defibrillators Improve Survival in End-Stage Renal Disease: Results from a Multi-Center Registry. *Am J Nephrol* 32:305-310., 2010

110. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT: Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. *68:818-825*, 2005
111. Hreybe H, Razak E, Saba S: Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. *Pacing Clin Electrophysiol* 30:1091-1095, 2007
112. Sakhuja R, Keebler M, Lai TS, McLaughlin Gavin C, Thakur R, Bhatt DL: Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. *Am J Cardiol* 103:735-741, 2009
113. Dasgupta A, Montalvo J, Medendorp S, Lloyd-Jones DM, Ghossein C, Goldberger J, Passman R: Increased complication rates of cardiac rhythm management devices in ESRD patients. *Am J Kidney Dis* 49:656-663, 2007
114. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 327:669-677, 1992
115. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 345:1667-1675, 2001
116. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 353:9-13, 1999
117. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 353:2001-2007, 1999
118. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 26:215-225, 2005
119. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 357:1385-1390, 2001
120. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL: Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 344:1651-1658, 2001

## Appendices

**Table 1. Characteristics of included studies**

Study ID: author, year, acronym (other publication)	N (N with CKD)	Study Design	Setting	Participants	Intervention (experimental group)	Intervention (control group)	Follow up (months)	Comments
<b>CKD and Transplant</b>								
Swedberg, 1987, CONSENSUS [31] (Swedberg 1988, 1990)	253	RCT	35 centres in Scandinavia	NYHA Class IV heart failure on digitalis and diuretics	Enalapril 5mg bd titrated to 20mg bd	Identical placebo	Mean=6	Terminated early by Ethical Review Committee; Excluded if creatinine>300µmol/L
Pfeffer, 1992, SAVE [114] (Tokmakova 2004)	2231 (719)	RCT	45 centres in the USA and Canada	Acute myocardial infarction LVEF≤40%	Captopril 12.5mg tds titrated up to 50mg tds	Identical placebo	Mean = 42±10	Excluded if creatinine>221µmol/L
Cohn, 2001, Val-HeFT [115] (Anand, 2009)	5010 (2916)	RCT	302 international centres	NYHA Class II-IV heart failure, LVEF≤40%	Valsartan 40mg bd titrated to 160mg bd	Identical placebo	Mean =23 (0 to 38)	93% on ACE inhibitor Excluded if creatinine>221µmol/L
CIBIS II, 1999 [116] (Erdmann, 2001; Castagno, 2010)	2657 (849)	RCT	274 centres in Europe	NYHA Class III-IV heart failure, LVEF≤35%, on ACE inhibitor	Bisoprolol 1.25mg daily titrated to 10mg daily	Identical placebo	Mean=15.6	Terminated early by Advisory and Safety Committee; Excluded if creatinine>300µmol/L
MERIT-HF, 1999 [117] (Ghali, 2009)	3991 (1469)	RCT	313 international centres	NYHA Class II-IV heart failure, LVEF≤40%, on ACE inhibitor	Metoprolol CR/XL 12.5 or 25mg daily titrated to 200mg daily	Identical placebo	Mean=12	Terminated early by Independent Safety Committee; No exclusion based on serum creatinine
Flather, 2005, SENIORS [118] (Cohen-Solal, 2009)	2135 (704)	RCT	11 European countries	Age≥70 years, heart failure admission or LVEF≤35%	Nebivolol 1.25mg daily titrated to 10mg daily	Identical placebo	Mean = 21±9	Excluded if “significant renal dysfunction” defined in methods paper as creatinine>250µmol/L
Dargie, CAPRICORN, 2001 [119] (Wali, 2011)	1959	RCT	163 international centres	Myocardial infarction within 3-21 days, LVEF≤40%, on ACE inhibitor	Carvedilol 6.25mg bd titrated to 25mg bd	Identical placebo	Mean=15.6	No exclusion based on serum creatinine
Packer, COPERNICUS, 2001 [120] (Wali, 2011)	2289	RCT	334 international centres	Symptoms at rest or minimal exertion, LVEF≤25%, on ACE inhibitor	Carvedilol 3.125mg bd titrated to 25mg bd	Identical placebo	10.4	Terminated early by Data Safety Monitoring Board; Excluded if creatinine>247.5 µmol/L

**The CARI Guidelines – Caring for Australasians with Renal Impairment**

CAPRICORN+COPERNICUS [48]	4217 (2566)							31 participants from the above 2 studies not included in this analysis
Pitt, RALES, 1999 [49]	1663 (not stated)	RCT	195 international centres	NYHA Class III-IV heart failure, LVEF≤35%, on ACE inhibitor	Spironolactone 25mg daily titrated to 50mg daily	Identical placebo	24	Terminated early by Data Safety Monitoring Board; Excluded if creatinine>221µmol/L or K>5.0mmol/L
Pitt, EPHEBUS, 2003 [50]	6642	RCT	674 international centres	Myocardial infarction within 3-14 days, LVEF≤40%, clinical features of heart failure	Eplerenone 25mg daily titrated to 50mg daily	Identical placebo	16 (0-33)	Excluded if creatinine>220µmol/L or K>5.0mmol/L
Zannad, EMPHASIS-HF, 2011 [51]	2737 (912)	RCT	278 international centres	Age≥55 years, NYHA Class II, LVEF≤30%, on maximal therapy	Eplerenone 25mg daily titrated to 50mg daily (25mg second daily titrated to 25mg daily if eGFR 30-50mL/minute)	Identical placebo	Median=21	Excluded if eGFR<30mL/minute or K>5.0mmol/L
DIG Trial, 1997 [54] (Shlipak, 2004)	6800 (3157)	RCT	302 centres in the USA and Canada	Clinical heart failure with LVEF≤45%, in sinus rhythm	Digoxin titrated according to an algorithm	Identical placebo	Mean=37 (28-58)	Excluded if creatinine>265µmol/L; 94% received ACE inhibitor, beta-blocker use not stated
<b>Dialysis</b>								
Cice, 2010 [90]	332	RCT	30 Italian centres	Haemodialysis 4X per week, NYHA Class II-III heart failure, LVEF≤40%, on ACE inhibitor	Telmartan 20mg daily titrated up to 80mg daily	Identical placebo	Mean=35.5±8.5 (2-40)	Approximately 60% on beta-blockers; 19/351 enrolled patients (5.4%) failed run-in
Cice, 2001, 2003 [99, 100]	114	RCT	Italy (number of centres not stated)	Haemodialysis 4X per week, NYHA Class II-III heart failure, LVEF≤35%,	Carvedilol 3.125mg bd titrated up to 25mg bd	Identical placebo	24 months (first 12 months for blinded echo outcomes, second 12 months unblended)	All on ACE inhibitor or ARB and digitalis; 18/132 (13.6%) failed the run-in

CONSENSUS=Cooperative North Scandinavian Enalapril Survival Study; SAVE=Survival and Ventricular Enlargement; Val-HeFT=Valsartan in Heart Failure Trial; CIBIS II=Cardiac Insufficiency Bisoprolol Study II; MERIT-HF=Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; SENIORS=Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure; CAPRICORN= Carvedilol Post-Infarct Survival Control in LV Dysfunction; RALES= Randomized Aldactone Evaluation Study; EPHESUS=Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; EMPHASIS-HF=Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; DIG=Digitalis Intervention Group;

Table 2. Quality of randomised trials

Study ID (author, year)	Method of allocation concealment *	Blinding			Intention-to-treat analysis †	Loss to follow up (%)	Quality Score
		(participants)	(investigators)	(outcome assessors)			
Swedberg, 1987, CONSENSUS [31]	Central	Yes	Yes	Yes	Yes	0	High
Pfeffer, 1992, SAVE [114] (Tokmakova 2004)	Central	Yes	Yes	Yes	Yes	6/2231 (<1%)	High
Cohn, 2001, Val-HeFT [115] (Anand, 2009)	Central	Yes	Yes	Yes	Yes – all patients appear to be included	None stated (8 had no baseline serum creatinine)	High
CIBIS II, 1999 [116] (Erdmann, 2001; Castagno, 2010)	Central	Yes	Yes	Yes	Yes	6/2647 (<1%)	High
MERIT-HF, 1999 [117] (Ghali, 2009)	Central	Yes	Yes	Yes	Yes	None stated (26 had no baseline serum creatinine)	High
Flather, 2005, SENIORS [118] (Cohen-Solal, 2009)	Central	Yes	Yes	Yes	Stated, but 7 randomised patients excluded from analysis (6 protocol violations in 1 centre, 1 did not receive study drug)	37/2128 (1.7%)	Medium
Dargie, CAPRICORN, 2001 [119] (Wali, 2010)	Central	Yes	Yes	Yes	Yes	None stated	High
Packer, COPERNICUS, 2001 [120] (Wali, 2010)	Central	Yes	Yes	Yes	Yes	0	High
Pitt, RALES, 1999 [49]	Not stated	Yes	Yes	Yes	Yes	None stated	High
Pitt, EPHEBUS, 2003 [50]	Central	Yes	Yes	Yes	Stated, but 10 excluded from one site due to data quality	17/6642 (<1%)	High

**The CARI Guidelines – Caring for Australasians with Renal Impairment**

Zannad, EMPHASIS-HF, 2011 [51]	Central	Yes	Yes	Yes	Yes	32/2737 (1.2%)	High
DIG Trial, 1997 [54] (Shlipak, 2004)	Central	Yes	Yes	Yes (Note that Investigators were outcome assessors)	Yes	93/6800 (1.4%)	High
Cice, 2010 [90]	Central	Yes	Yes	Yes (Not clear who assessed outcomes)	Yes	0	High
Cice, 2001, 2003 [99, 100]	Unclear	Yes	Yes	Yes (Not clear who assessed outcomes)	Yes	0	Low – reduced by unblinding for the second 12 months and apparent lack of independent assessment of outcomes

**Table 3a. Results for dichotomous outcomes: all-cause mortality in CKD and transplant**

Study ID (author, year, acronym)	Intervention group (number of patients with events/number of patients exposed)	Control group (number of patients with events/number of patients not exposed)	Relative risk (RR) [95% CI]	Risk difference (RD) [95% CI]	Comment
<b><u>RAS antagonist</u></b>					
Swedberg, 1988, CONSENSUS [33]	24%	50%	52% reduction (p=0.002)	NR	Crude mortality in patients with creatinine>120µmol/L (the median). Numbers not provided.
Tokmakova, 2004, SAVE [34]	96/359 (26.7%)	127/360 (35.3%)	“Relative Risk reduction” 28% (6- 45)	NR	
Anand, 2009, Val-HEFT [30]	362/1477 (24.5%)	341/1439 (23.7%)	1.01 (0.8501.20)	NR	Time to first morbid event significantly different
<b><u>Beta-blocker</u></b>					
Erdmann, 2001, CIBIS II [45]	67/434	97/415	0.66 (0.50-0.87)	NR	
Ghali, 2009, MERIT-HF [46]	63/735	105/734	0.60 (0.45-0.80)	NR	Numbers presented separately for GFR<45 and GFR 45-60. Number are the sum of these.
Cohen-Solal, 2009, SENIORS [47]	71/348	92/356	0.79 (0.60-1.04)	NR	
Wali, 2011, CAPRICORN and COPERNICUS [48]	181/1293	233/1273	0.76 (0.64-0.91)	NR	
Badve (JACC, In press), Systematic Review	382/2810	527/2778	0.72 (0.64-0.81)		P for heterogeneity=0.435, I <sup>2</sup> =0%

**The CARI Guidelines – Caring for Australasians with Renal Impairment**

<b><u>Aldosterone antagonist</u></b>					
Pitt, RALES, 1999 [49]	Not stated	Not stated	0.8 (0.65-0.95)	NR	Patients with creatinine $\geq$ 106 $\mu$ mol/L (inferred from Figure 2 of paper)
Pitt, EPHEBUS, 2003 [50]	Not stated	Not stated	0.9 (0.8-1.1)	NR	Patients with creatinine $\geq$ 96 $\mu$ mol/L (inferred from Figure 2A of paper)
Zannad, EMPHASIS-HF, 2011 [51]	Not stated	Not stated	0.70 (0.55-0.85)	NR	Patients with eGFR $<$ 60mL/minute (inferred from Figure 2 of paper)
<b><u>Digoxin</u></b>					
DIG Trial, 1997 [54] (Shlipak, 2004)	Not stated	Not stated	0.95 (0.85-1.07) for GFR 30-60 0.93 (0.65 to 1.35) for GFR $<$ 30		N=2,939 with GFR 30-60mL/min N=218 with GFR $<$ 30mL/min
<b><u>ESA</u></b>					
<b><u>Volume state</u></b>					
<b><u>Implantable devices</u></b>					

Table 3b. Results for dichotomous outcomes: all-cause mortality in dialysis

Study ID (author, year, acronym)	Intervention group (number of patients with events/number of patients exposed)	Control group (number of patients with events/number of patients not exposed)	Relative risk (RR) [95% CI]	Risk difference (RD) [95% CI]	Comment
<b><u>RAS antagonist</u></b>					
Cice, 2010 [90]	58/165	91/167	0.51; 95% CI: 0.32 to 0.82		Adjusted hazard ratio for mortality
<b><u>Beta-blocker</u></b>					
Cice, 2001, 2003 [99, 100]	30/58	41/56	0.51 (0.32-0.82)		Adjusted hazard ratio for mortality
<b><u>Aldosterone antagonist</u></b>					
<b><u>Digoxin</u></b>					
<b><u>ESA</u></b>					

---

<u>Volume state</u>					
<u>Implantable devices</u>					